Психологическая подготовленность хоккейных вратарей как предиктор их соревновательной надежности

Рукопись поступила в редакцию: 11.01.2022.Received: 11.01.2022.В тезисах представлен проект предстоящего исследования. На основании обобщения многолетнего авторского практического опыта, анализа и систематизации данных обосновывается важность последовательного формирования и совершенствования психологической подготовленности хоккейных вратарей с учетом врожденных индивидуальных особенностей путем реализации научно-обоснованной программы психолого-педагогических воздействий согласно спортивной периодизации. Научно обоснованные подходы в выборе инструментов и методов для практической реализации будут способствовать обеспечению конкурентных преимуществ и соревновательной надежности игроков.The theses present a draft of the upcoming study. The research is basis on the generalization of the author’s many years of practical experience, analysis and systematization of data. The importance of the consistent formation and improvement of hockey goaltenders psychological preparedness substantiated. The scientifically based program of psychological and pedagogical influences consider innate individual characteristics and in accordance to sports periodization implementation as well as the choice of tools and methods for practical application will help to ensure players’ competitive advantages and competitive reliability

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by 18F-FDG PET

articl

Effect of Rimsulfuron, Imazapic and Imazamox Herbicides on Broomrape (Orobanche aegyptiaca) in Tomato (Lycopersicum esculentum)

Experiments, in Petri dish and greenhouse, were carried out to investigate the efficiency of three herbicides (rimsulfuron, imazapic and imazamox) in controling broomrape. In Petri dish study, herbicides were applied at 0.05, 0.25, 1.25, 6.25 and 31.25 micro-mole doses to broomrape seeds at germination stage without a host plant and adding GR24 as stimulator. In the greenhouse experiments, the efficiency of these herbicides to control broomrape in two varieties of tomato (Viva and Hyb.Petopride II) was investigated. Treatments were four doses of rimsulfuron (25, 50, 75 and 100 g ai/ha), imazapic (5, 10, 15 and 20 g ai/ha) and imazamox (0.4, 0.8, 1.2 and 1.6 g ai/ha) at one, two and three applications. Results of Petri-dish experiments showed that rimsulfuron and imazapic significantly reduced radicle elongation of seedlings as compared to the control, while, imazamox did not have any effect on broomrape seed. Each dose was applied for one, two and three times with in 15, 29 and 43 days after within transplanting tomato seedlings. Results of pot experiments indicated that the responses of two tomato varieties herbicides were different. Viva was responsive to herbicidal effect and produced higher biomass than Hyb.Petopride II. Rimsulfuron was a suitable herbicide in tomato to control broomrape. Rimsulfuron at doses of 25, 50 and 75 g ai/ha (three times of application) were the best doses, specially in viva were the best treatments for broomrape control and producing tomato biomass. Imazapic also, at 5 g ai/ha (two times of application) and 10 g ai/ha (single application) was an effective treatments in variety of viva. Imazamox treatments did not appear to be suitable herbicides in this study

The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2

Thrombosis and Hemostasi